In these GBM cells, VRK1 was depleted and treated with TMZ 50 and 200 μM, olaparib 5 μM, and the combination of TMZ 50 and olaparib 5 μM for 24 h to determine their effect on chromatin relaxation associated to H4K16ac changes (Figure 2). The gene discussed is VRK1; the disease is glioblastoma.